COMPOSITIONS CAPABLE OF REDUCING ELEVATED BLOOD UREA CONCENTRATION

Inventors: Robert Benner, Barendrecht (NL); Nisar Ahmed Khan, Rotterdam (NL)

Assignee: Biotemp B.V., Koekange (NL)

Notice: This patent is subject to a terminal disclaimer.

Filed: Mar. 17, 2011

Reissued Patent

U.S. Patent

Patent Number: US RE43,279 E
Date of Reissued Patent: *Mar. 27, 2012

Related U.S. Patent Documents

Patent No.: 7,576,174
Issued: Aug. 18, 2009
Appl. No.: 11/346,450
Filed: Feb. 2, 2006

U.S. Applications:
Continuation-in-part of application No. 11/249,541, filed on Oct. 13, 2005, now abandoned, which is a continuation-in-part of application No. 1/CL/EP2005/03707 filed on Apr. 8, 2005, and a continuation-in-part of application No. 10/821,256, filed on Apr. 8, 2004, now abandoned, and a continuation-in-part of application No. 10/262,522, filed on Sep. 30, 2002, now Pat. No. 7,365,155, which is a continuation of application No. 1/CL/NI/01/00259, filed on Mar. 29, 2001.

Foreign Application Priority Data
Mar. 29, 2000 (EP) 00201139

Int. Cl.
C07K 2/00 (2006.01)

U.S. Cl. 530/300; 530/330; 514/2

Field of Classification Search None

References Cited

U.S. PATENT DOCUMENTS
4,977,244 A 12/1990 Muchmore et al.
5,010,175 A 4/1991 Rutter et al.
5,009,834 A 5/1994 Scott et al.
5,436,270 A 7/1995 Wang
5,650,489 A 7/1997 Lam et al.
5,677,275 A 10/1997 Lunardi-Iskandar et al.
5,851,997 A 12/1998 Harris
5,854,004 A 12/1998 Czerwiński et al.
5,942,494 A 8/1999 Ginsberg et al.
5,958,413 A 9/1999 Anagnostopoulos et al.
5,968,513 A 10/1999 Gallo et al.
5,997,871 A 12/1999 Gallo et al.
6,022,696 A 2/2000 Harding et al.
6,319,504 B1 11/2001 Gallo et al.
6,361,992 B1 3/2002 Szadzinski et al.
6,489,296 B1 12/2002 Grinnell et al.
6,507,788 B1 1/2003 Camara y Ferrer et al.
6,586,403 B1 7/2003 Mathison et al.
6,596,488 B1 7/2003 Gallo et al.
6,642,201 B1 11/2003 Khavinson et al.
6,727,227 B1 4/2004 Khavinson
6,844,315 B2 1/2005 Khan et al.
6,821,751 B1 7/2005 Khan et al.

FOREIGN PATENT DOCUMENTS
DE 3715662 11/1987
DE 19953339 5/2001
EP 0 572 688 5/1997
EP 1 300 418 4/2003
EP 1 224 212 B1 7/2003
FR 2 706 772 12/1994
JP 09-176187 A 7/1997

OTHER PUBLICATIONS

(Continued)

Primary Examiner — Yunsoo Kim
(74) Attorney, Agent, or Firm — TraskBritt

ABSTRACT
The invention includes a method of reducing urea concentration in a subject’s serum. Such a method comprises administering to the subject (e.g., a mammal such as a human) a composition comprising an oligopeptide (or oligopeptides) having activity in reducing urea concentration in the subject’s serum as determined by a mouse renal reperfusion test, wherein the oligopeptide comprises the sequence AQG or MTRV (SEQ ID NO:1), AQGV (SEQ ID NO:2) or LAGV (SEQ ID NO:4).

4 Claims, 3 Drawing Sheets
Daemen et al., Ischemia-reperfusion-induced IFN-$\gamma$-gamma up-regulation: involvement of IFN-$\gamma$-gamma and IFN-$\gamma$-gamma. The Journal of Immunology, 1999, pp. 5506-5510, vol. 162. 
Huang et al., Ischemia-reperfusion and immediate T cell responses, Cellular Immunology, 2007, pp. 4-11, vol. 248. 
Olzyny et al., Levels of Inhibitors of Tumor Necrosis Factor Alpha and Interleukin Ib in Urine and Sera of Patients with Urosepsis, Infection and Immunity, Aug. 1998, pp. 3527-3534. 
Wu et al., Gonadotropin-Releasing Hormone (GNRH) Cleavage Products are Involved in the Regulation of GNRH Gene Expression in the GT1-7 Neuronal Cell Line, Society for Neuroscience Abstracts, Nov. 4, 2000, pp. 7.8, XP000901566, vol. 26, No. 1-2. 
U.S. Appl. No. 11/600,294, filed Nov. 15, 2006, Oligopeptide Acetate and Formulations Thereof. 
Connelly et al., Biphasic Regulation of NF-κB Activity Underlies the Pro- and Anti-Inflammatory Actions of Nitric Oxide, The Journal of Immunology, 2001, pp. 3873-3881, 166, The American Association of Immunologists, USA.
Khavinson et al., Gerontological Aspects of Genome Peptide Regulation, 2005, S. Karger AG, Basel, Switzerland.
Op 24 uur post-reperfusie:
(C-term: CARBOXYL; N-term: FREE)
- A \hspace{1cm} p=0.0491 NMPF-47 LAGV
- B \hspace{1cm} p=0.0008 NMPF-46 AQQV
- C \hspace{1cm} p=0.9248 NMPF-44 LAG
- D \hspace{1cm} p=0.4043 NMPF-43 AQQ
- E \hspace{1cm} p=0.1848 NMPF-12 MTRV
- F \hspace{1cm} p=0.106 NMPF-11 MTRV
- G \hspace{1cm} p=0.1389 NMPF-7 VLPALPQ
- H \hspace{1cm} p=0.5613 NMPF-6 VLPALP
- I \hspace{1cm} p=0.9301 NMPF-4 LQGV
- J \hspace{1cm} p=0.0030 NMPF-3 LQG

Op 72 uur post-reperfusie:
(C-term: CARBOXYL; N-term: FREE)
- A \hspace{1cm} p=0.0017 NMPF-47 LAGV
- B \hspace{1cm} p<0.0001 NMPF-46 AQQV
- C \hspace{1cm} p=0.8186 NMPF-44 LAG
- D \hspace{1cm} p=0.2297 NMPF-43 AQQ
- E \hspace{1cm} p=0.0242 NMPF-12 MTR
- F \hspace{1cm} p=0.0021 NMPF-11 MTRV
- G \hspace{1cm} p=0.0049 NMPF-7 VLPALPQ
- H \hspace{1cm} p=0.3297 NMPF-6 VLPALP
- I \hspace{1cm} p=0.8328 NMPF-4 LQGV
- J \hspace{1cm} p=0.9445 NMPF-3 LQG

FIG. 1
Serum urea values following 25 minutes of renal ischemia

(Mean ± SEM)

FIG. 2
COMPOSITIONS CAPABLE OF REDUCING ELEVATED BLOOD UREA CONCENTRATION

Matter enclosed in heavy brackets [ ] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue.

CROSS-REFERENCE TO RELATED APPLICATIONS


TECHNICAL FIELD

The invention relates generally to biotechnology, and more specifically to compositions having immunoregulatory activity, which compounds include particular oligopeptides derived from human chorionic gonadotropin ("hCG").

BACKGROUND

U.S. Pat. No. 5,380,668 to Herron (Jun. 10, 1995), the contents of the entirety of which are incorporated by this reference, discloses, among other things, various compounds having the antigenic binding activity of hCG. The oligopeptides disclosed therein are disclosed generally for use in diagnostic methods.

Various patents and patent applications to Gallo et al. (e.g., U.S. Pat. No. 5,677,275 (corresponding to WO96/04008 A1), U.S. Pat. No. 5,877,148 (also corresponding to WO96/04008 A1), WO 97/49721 A1, U.S. Pat. No. 6,319,504 (corresponding to WO 97/49373), U.S. Patent Application 2003/004273 A1 (also corresponding to WO 97/49373), U.S. Pat. No. 5,968,513 (corresponding to WO 97/49418), U.S. Pat. No. 5,997,871 (corresponding to WO 97/49432), U.S. Pat. Nos. 6,620,416, 6,596,688, WO 01/11048 A2, WO 01/10907 A2, and U.S. Pat. No. 6,583,109) relate to various oligopeptides and their use in, among other things, “inhibiting HIV infection,” “treatment or preventing HIV infection,” “treatment or preventing cancer,” “treating or preventing a condition characterized by loss of body cell mass,” “treating or preventing a condition associated with pathological angiogenesis,” “treating or preventing hematopoietic deficiency,” “ex vivo gene therapy,” “expanding blood cells in vitro,” and/or “providing blood cells to a subject.”

DISCLOSURE OF THE INVENTION


The invention includes a method of reducing blood urea nitrogen (BUN) concentration (herein also called urea concentration) in a subject’s serum. Such a method comprises administering to the subject (e.g., a mammal such as a human) a composition comprising an oligopeptide (or oligopeptides) having activity in reducing urea concentration in the subject’s serum as determined by a mouse renal reperfusion test, wherein the oligopeptide comprises the sequence AQG or LAQV (SEQ ID NO:4), or AQGV (SEQ ID NO:2) or MTRV (SEQ ID NO:1).

The oligopeptide of the composition will typically be from three (3) to twelve (12) amino acids in length. In the case where the composition includes the oligopeptide AQG or LAQV (SEQ ID NO:4) or AQGV (SEQ ID NO:2), the composition may be administered orally. The oligopeptide will preferably be of synthetic origin (e.g., produced by a Merrfield synthesis). When the composition is administered to the subject parenterally, the composition will typically consist essentially of oligopeptide and PBS (e.g., in an amount of from about 0.25 to about 10 mg/kg body mass of the subject).

The invention is thought to be useful for instances, when, for example, the subject is undergoing acute renal failure, especially when the subject is undergoing persistent oliguria, is not producing more than ½ ml urine per hour per kilogram body mass of the subject, and/or has a serum potassium level greater than 6.5 mmol per liter serum.

In one preferred embodiment, the invention involves administering a purified, synthetic or isolated peptide consisting of AQGV (SEQ ID NO:2), or an acid addition salt thereof. A typical dosage of this peptide will vary from about 0.5 to about 35 mg/kg body weight of the subject.

In another preferred embodiment, typically when a relatively low dosage is preferred, the invention involves administering a purified, synthetic or isolated peptide consisting of AQG, or an acid addition salt thereof at, for example, a dosage of the peptide from about 0.1 to about 10 mg/kg body weight of the subject.

The invention also provides use of a composition according to the invention for the preparation of a pharmaceutical composition or medicament for the treatment of a disorder such as acute renal failure. Such a composition is preferably prepared using a purified, synthetic or isolated peptide consisting of AQG or AQGV (SEQ ID NO:2) or LAQV (SEQ ID NO:4) or MTRV (SEQ ID NO:1), or an acid addition salt thereof. Most preferably, AQG (when low dosages are preferred) or AQGV (SEQ ID NO:2) is used.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 graphically depicts the results of Example 1. Shown are the BUN (urea) values at the various points in time after treatment with peptides A to F or without treatment (control).

FIG. 2 graphically depicts the results of Example 4. Shown are the BUN (urea) values at the various points in time after treatment with varying dosages of peptide D or peptide B or without treatment (PBS).
Fig. 3 depicts the blood urea values of Example 4 at 0, 24, and 72 hours post-clamping after administration of "peptide D" AQG and "peptide B" AQGV (SEQ ID NO:2). PBS control compared to peptide administered groups.

**DETAILED DESCRIPTION OF THE INVENTION**

As used herein, a “purified, synthetic or isolated” peptide is one that has been purified from a natural or biotechnological source, or, more preferably, is synthesized as described herein.

“Composition,” as used herein, refers to chemical compounds that contain or consist of the oligopeptide. The oligopeptide is preferably isolated before inclusion within the composition. The oligopeptide most preferably consists of three (3) to six (6) amino acids.

For instance, the previously described preferred compounds could, in one embodiment be:

HT A Q G V CT

wherein NT at the N-terminus is selected from the group of H—, CH3—, an acyl group, or a general protective group; and CT at the C-terminus is selected from the group of small (e.g. 1 to 5 amino acids) peptides, —OH, —OR, —NH2, —NHR, —NR2R, or —N(CH3)2NR2R, wherein R2R, when present, are independently selected from H, alkyl, aryl, (aryl)alkyl, and wherein R2R can be cyclically bonded to one another.

“Alkyl” as used herein, is preferably a saturated branched or unbranched hydrocarbon having one to six carbon atoms, for example, methyl, ethyl, and isopentyl.

“Aryl” as used herein, is an aromatic hydrocarbon group, preferably having 6 to 10 carbon atoms, such as phenyl or naphthyl.

“(Aryl)alkyl” as used herein, is an aryl group (having both aliphatic and aromatic portions), preferably having 7 to 13 carbon atoms such as benzyl, ethylbenzyl, n-propylbenzyl, and isobutylbenzyl.

“Oligopeptide” as used herein, are peptides having from 3 to 12 amino acids joined together by peptide bonds. Equivalent to oligopeptides are compounds having the same or equivalent side chains as the particular amino acids used in an oligopeptide, and arranged sequentially in the same order as the peptides, but joined together by non-peptide bonds, e.g., by isosteric linkages such as the keto isostere, hydroxy isostere, diketo isostere, or the keto-difluoromethylenic isostere.

“Composition” also includes, for example, an acceptable salt of the oligopeptide or a labeled oligopeptide. As used herein, “acceptable salt” refers to salts that retain the desired activity of the oligopeptide or equivalent compound, but preferably do not detrimentally affect the activity of the oligopeptide or other component of a system in which uses the oligopeptide. Examples of such salts are acid addition salts formed with inorganic acids, for example, hydrochloric acid, hydrobromic acid, sulfonic acid, phosphoric acid, nitric acid, and the like. Salts may also be formed with organic acids such as, for example, acetic acid, oxalic acid, tartaric acid, succinic acid, maleic acid, fumaric acid, gluconic acid, citric acid, malic acid, ascorbic acid, benzoic acid, tannic acid, pamoic acid, alginic acid, polyglutamic acid, and the like. Salts may be formed with polyvalent metal cations such as zinc, calcium, bismuth, barium, magnesium, aluminum, copper, cobalt, nickel and the like or with an organic cation formed from N,N'-dibenzylethylenediamine or ethylenediamine, or combinations thereof (e.g., a zinc tannate salt).

The invention also provides use of an oligopeptide having activity in reducing urea concentration in a subject's serum as determined by a mouse renal reperfusion test, the oligopeptide preferably comprising the sequence AQG or MTGQ (SEQ ID NO:1) or 1-AQGV (SEQ ID NO:4), in the production of a pharmaceutical composition for reducing urea concentration in a subject's serum, in particular when the subject is undergoing acute renal failure. It is preferred that the oligopeptide to be used in the production of the pharmaceutical composition consists of AQGV (SEQ ID NO:2).

Such a pharmaceutical composition may be administered to the subject parenterally or orally. Such a pharmaceutical composition may consist essentially of oligopeptide and PBS. It is preferred that the oligopeptide is of synthetic origin. Suitable treatment for example entails administering the oligopeptide in the pharmaceutical composition to the patient intravenously in an amount of from about 0.1 to about 35 mg/kg body mass of the subject. It may be useful that the pharmaceutical composition consists essentially of from one to three different oligopeptides.

Such treatment is in particular preferred when the subject is undergoing persistent oliguria, for example when the subject's kidneys are not producing more than 0.5 ml urine per hour per kilogram body mass of the subject, or when the subject has a serum potassium level greater than 6.5 mmol per liter serum.

The thus developed chemical entity can be administered and introduced in vivo systemically, topicaly, or locally. The peptide, or its modification or derivative, can be administered as the entity as such or as a pharmaceutically acceptable acid- or base addition salt, formed by reaction with an inorganic acid (such as hydrochloric acid, hydrobromic acid, perchloric acid, nitric acid, thiocyanic acid, sulfuric acid, and phosphoric acid); or with an organic acid (such as formic acid, acetic acid, propionic acid, glycolic acid, lactic acid, pyruvic acid, oxalic acid, malonic acid, succinic acid, malic acid, and fumaric acid); or by reaction with an inorganic base (such as sodium hydroxide, ammonium hydroxide, potassium hydroxide); or with an organic base (such as mono-, di-, trialkyl and aryl amines and substituted ethanolamines). A selected peptide and any of the derived entities may also be conjugated to sugars, lipids, other polypeptides, nucleic acids and PNA; and function in situ as a conjugate or be released locally after reaching a targeted tissue or organ.

A “substitution” with regard to the various amino acids generally relate to substituting a group such as alloxy, halogen, hydroxy, nitro, or lower alkyl onto an aromatic ring for hydrogen that would usually be present. Substitutions can also be made on the alkyl chain connecting the aromatic portion to the peptide backbone, with, for instance lower alkyl groups substituting for hydrogen. Still further substitutions can be made at the alpha position of an amino acid, also using an alkyl group.

Preferred substitutions involve the use of fluorine or chlorine as a halogen, and methoxy as an alkoxyl group. With regard to alkyl and lower alkyl, generally alkyl groups having fewer (1 to 3) carbon atoms are preferred.

The compounds according to the general formula may be prepared in a manner conventional for such compounds. To that end, suitably N alpha protected (and side-chain protected if reactive side-chains are present) amino acid derivatives or peptides are activated and coupled to suitably carboxyl protected amino acid or peptide derivatives either in solution or on a solid support. Protection of the alpha-amino functions generally takes place by urethane functions such as the acid-labile tertiary-butyl-oxycarbonyl group ("Boc"), benzoyl-oxycarbonyl ("Z") group and substituted analogs or the base-
labile 9-fluoremyl-methyloxycarbonyl ("Fmoc") group. The Z group can also be removed by catalytic hydrogenation. Other suitable protecting groups include the Nps, Bmn, Bpoc, Aloc, Msc, etc. A good overview of amino protecting groups is given in The Peptides, Analysis, Synthesis, Biology, Vol. 3 E. Gross and J. Meienhofer, eds. (Academic Press, New York, 1981). Protection of carboxyl groups can take place by ester formation, for example, base-labile esters like methyl or ethyl, acid labile esters like tert, butyl or, substituted, benzyl esters or hydroxynitrogenlytically. Protection of side-chain functions like those of lysine and glutamic or aspartic acid can take place using the aforementioned groups. Protection of thiol, and although not always required, of guanidino, alcohol and imidazole groups can take place using a variety of reagents such as those described in The Peptides, Analysis, Synthesis, Biology, id. or in Pure and Applied Chemistry, 59(3), 331-344 (1987). Activation of the carboxyl group of the suitably protected amino acids or peptides can take place by the azide, mixed anhydride, active ester, or carbodiimide method especially with the addition of catalytic and racemization-suppressing compounds like 1-N-N-hydroxybenzotriazole, N-hydroxysuccinimide, 3-hydroxy-4-oxo-3,4-dihydro-1,2,3-benzotriazine, N-hydroxy-5norbomene-2,3-dicarboximide. Also the anhydrides of phosphorus based acids can be used. See, e.g., The Peptides, Analysis, Synthesis, Biology, supra and Pure and Applied Chemistry, 59(3), 331-344 (1987).

It is also possible to prepare the compounds by the solid phase method of Merrifield. Different solid supports and different strategies are known see, e.g. Barany and Merrifield in The Peptides, Analysis, Synthesis, Biology, Vol. 2, E. Gross and J. Meienhofer, eds. (Acad. Press, New York, 1980), Kueib-Cordonier and Mullen Int. J. Peptide Protein Res., 30, 705-739 (1987) and Fields and Noble Int. J. Peptide Protein Res., 35, 161-214 (1990). The synthesis of compounds in which a peptide bond is replaced by an isostere, can, in general, be performed using the previously described protecting groups and activation procedures. Procedures to synthesize the modified isosteres are described in the literature e.g. for the —CH₂—NH— isostere and for the —CO—CH₂— isostere.

Removal of the protecting groups, and, in the case of solid phase peptide synthesis, the cleavage from the solid support, can take place in different ways, depending on the nature of those protecting groups and the type of linker to the solid support. Usually deprotection takes place under acidic conditions and in the presence of scavengers. See, e.g. volumes 3, 5 and 9 of the series on The Peptides Analysis, Synthesis, Biology, supra.


Although possibly not desirable from an economic point of view, oligopeptides according to the invention could also be made according to recombinant DNA methods. Such methods involve the preparation of the desired oligopeptide thereof by means of expressing recombinant polynucleotide sequence that codes for one or more of the oligopeptides in question in a suitable microorganism as host. Generally the process involves introducing into a cloning vehicle (e.g., a plasmid, phage DNA, or other DNA sequence able to replicate in a host cell) a DNA sequence coding for the particular oligopeptide or oligopeptides, introducing the cloning vehicle into a suitable eucaryotic or prokaryotic host cell, and cultivating the host cell thus transformed. When a eucaryotic host cell is used, the compound may include a glycoprotein portion.

As used herein, a “functional analogue” or “derivative” of a peptide includes an amino acid sequence, or other sequence monomers, which has been altered such that the functional properties of the sequence are essentially the same in kind, not necessarily in amount. An analogue or derivative can be provided in many ways, for instance, through “conservative amino acid substitution.” Also peptidomimetic compounds can be designed that functionally or structurally resemble the original peptide taken as the starting point but that are for example composed of non-naturally occurring amino acids or polyamides. With “conservative amino acid substitution,” one amino acid residue is substituted with another residue with generally similar properties (size, hydrophobicity), such that the overall functioning is likely not to be seriously affected. However, it is often much more desirable to improve a specific function. A derivative can also be provided by systematically improving at least one desired property of an amino acid sequence. This can, for instance, be done by an Ala-scan and/or replacement net mapping method. With these methods, many different peptides are generated, based on an original amino acid sequence but each containing a substitution of at least one amino acid residue. The amino acid residue may either be replaced by alanine (Ala-scan) or by any other amino acid residue (replacement net mapping). This way, many positional variants of the original amino acid sequence are synthesized. Every positional variant is screened for a specific activity. The generated data are used to design improved peptide derivatives of a certain amino acid sequence.

A derivative or analogue can also be, for instance, generated by substitution of an L-amino acid residue with a D-amino acid residue. This substitution, leading to a peptide that does not naturally occur in nature, can improve a property of an amino acid sequence. It is, for example, useful to provide a peptide sequence of known activity of all D-amino acids in retro inversion format, thereby allowing for retained activity and increased half-life values. By generating many positional variants of an original amino acid sequence and screening for a specific activity, improved peptide derivatives comprising such D-amino acids can be designed with further improved characteristics.

A person skilled in the art is well able to generate analogous compounds of an amino acid sequence. This can, for instance, be done through screening of a peptide library. Such an analogue has essentially the same functional properties of the sequence in kind, not necessarily in amount. Also, peptides or analogues can be circularized, for example, by providing them with (terminal) cysteines, dimerized or multimerized, for example, by linkage to lysine or cysteine or other compounds with side-chains that allow linkage or multimerization, brought in tandem- or repeat-configuration, conjugated or otherwise linked to carriers known in the art, if only by a labile link that allows dissociation.

Synthetic versions of these oligopeptides as described above, and functional analogues or derivatives or breakdown products, are herein provided to lower BUN concentration be used in methods to the treatment of disease.

The term “pharmaceutical composition” as used herein is intended to cover both the active composition of the invention alone or a composition containing the composition of the invention together with a pharmaceutically acceptable carrier, diluent or excipient. Acceptable diluents of an oligopeptide as described herein in the detailed description are for example physiological salt solutions or phosphate buffered
salt solutions. In one embodiment, an oligopeptide or composition is administered in an effective concentration to an animal or human systemically, for example, by intravenous, intra-muscular or intraperitoneal administration. Another way of administration comprises perfusion of organs or tissue, be it in vivo or ex vivo, with a perfusion fluid comprising an oligopeptide or composition according to the invention. The administration may be done as a single dose, as a discontinuous sequence of various doses, or continuously for a period of time sufficient to permit substantial modulation of gene expression. In the case of a continuous administration, the duration of the administration may vary depending upon a number of factors that would readily be appreciated by those skilled in the art.

The administration dose of the active molecule may be varied over a fairly broad range. The concentrations of an active molecule that can be administered would be limited by efficacy at the lower end and the solubility of the compound at the upper end. The optimal dose or doses for a particular patient should and can be determined by the physician or medical specialist involved, taking into consideration well-known relevant factors such as the condition, weight and age of the patient, etc.

The active molecule may be administered directly in a suitable vehicle, such as, for example, phosphate-buffered saline (“PBS”) or solutions in alcohol or DMSO. Pursuant to preferred embodiments of the present invention, however, the active molecule is administered through a single dose delivery using a drug-delivery system. A suitable drug-delivery system would be pharmacologically inactive or at least tolerable. It should preferably not be immunogenic nor cause inflammatory reactions, and should permit release of the active molecule so as to maintain effective levels thereof over the desired time period. Alternatives are known in the art as suitable for purposes of sustained release and are contemplated as within the scope of the present invention. Suitable delivery vehicles include, but are not limited to, the following: microcapsules or microspheres; liposomes and other lipid-based release systems; viscous instillates; absorbable and/or biodegradable mechanical barriers and implants; and polymeric delivery materials, such as polyethylene oxide/polypropylene oxide block copolymers, polysters, crosslinked polyvinyl alcohols, polyanhydrides, polymethacrylate and poly(ethylene)hydrogels, anionic carbohydrate polymers, etc. Useful delivery systems are well known in the art.

One formulation to achieve the active molecule release comprises injectable microcapsules or microspheres made from a biodegradable polymer such as lactic acid, glycolide, and caprolactone polymers) may also be used in formulations other than microcapsules and microspheres; e.g., pre-made films and spray-on films of these polymers containing the active molecule would be suitable for use in accordance with the present invention. Fibers or filaments comprising the active molecule are also contemplated as within the scope of the present invention.

Another highly suitable formulation for a single-dose delivery of the active molecule in accordance with the present invention involves liposomes. The encapsulation of an active molecule in liposomes or multilamellar vesicles is a well-known technique for targeted drug delivery and prolonged drug residence. The preparation and use of drug-loaded liposomes is well within the reach of persons skilled in the art and well documented in the literature.

Yet another suitable approach for single-dose delivery of an active molecule in accordance with the present invention involves the use of viscous instillates. In this technique, high molecular weight carriers are used in admixture with the active molecule, giving rise to a structure that produces a solution with high viscosity. Suitable high molecular weight carriers include, but are not limited to, the following: dextrins and cycloadextrins; hydrogels; (cross-linked) viscous materials, including (cross-linked) viscoelastics; carboxymethylcellulose; hyaluronic acid; and chondroitin sulfate. The preparation and use of drug-loaded viscous instillates is well known to persons skilled in the art.

Pursuant to yet another approach, the active molecule may be administered in combination with absorbable mechanical barriers such as oxidized regenerated cellulose. The active molecule may be covalently or non-covalently (e.g., ionically) bound to such a barrier, or it may simply be dispersed therein.

The invention is further explained with the aid of the following illustrative examples.

EXAMPLES

Example 1

Six oligopeptides (i.e., A: LAGV (SEQ ID NO:4), B: AQQV (SEQ ID NO:2), C: LAG, D: AQG, E: MTR, and F: MTRV (SEQ lp NO:1)) were tested and compared with PBS (control) in a double blind animal study for each peptide's relative ability to aid recovery in a mouse renal ischemia reperfusion test. In this test, the mice were anesthetized, and one kidney from each mouse was removed. The other kidney was tied off for 25 minutes, and the serum urea levels were allowed to increase. Both before and after tying off, each of the separate peptides was administered to thirty (30) different mice (5 mg oligopeptide/kg body mass intravenously), after which, the mortality of the mice was determined for each oligopeptide as well as was the BUN concentration at two hours, 24 hours and 72 hours. The results are shown in Fig. 1 and (excluding the results of peptide A (LAGV (SEQ ID NO:4)) obtained in example 1) in Table 2 below.

Under inhalation anesthesia, the left kidney with its artery and vein was isolated and occluded for 25 minutes using a microvascular clamp. During surgery animals were placed on a heating path to maintain body temperature at 37°C. Five minutes before placing the clamp, and 5 minutes before releasing the clamp, 5 mg/kg of peptide, dissolved in 0.1 ml. of sterile saline, was administered intravenously. After reperfusion of the left kidney the right kidney was removed. Kidney function was assessed by measuring blood urea nitrogen before clamping, and at 2, 24, and 72 hours after reperfusion.
## TABLE 1

Results - (mortality at 72 hours post-reperfusion).

<table>
<thead>
<tr>
<th>Peptide</th>
<th>PBS</th>
<th>A (LAGV)</th>
<th>B (AQGV)</th>
<th>C (MTRV)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Survival</td>
<td>6/10</td>
<td>6/10</td>
<td>0/10</td>
<td>10/10</td>
</tr>
<tr>
<td>Serum Urea</td>
<td></td>
<td>4/10</td>
<td>0/10</td>
<td>10/10</td>
</tr>
</tbody>
</table>

*P < vs PBS

2 mice surviving and the serum urea levels being much lower than in the other groups. However, the oligopeptides LAG, AQG, and MTR, in this experiment having no reducing effect on BUN concentration, each caused a significant reduction of mortality compared to the PBS control, where MTR did significantly raise BUN levels in the tested mice at 72 hrs.

---

### Example 2

One oligopeptide (A: (LAGV SEQ ID NO:4)) was retested for its capacity to reduce BUN levels in the mice test for the reasons as described above. The results are shown in Table 2 below. As can be seen, mice administered the oligopeptide LAGV (SEQ ID NO:4) now did much better in terms of both survival (a significant reduction in mortality versus the PBS control group) and reduced BUN concentration than the control group (PBS).

### Example 3

Four additional oligopeptides (G (VLPALPQ SEQ ID NO:5), H (VLPA PQ SEQ ID NO:6), I (LQGV SEQ ID NO:3) and J (LQJ)) were tested for their capacity to reduce BUN levels in the mice test as described above. The results are shown in Table 2 below. As can be seen, mice administered the oligopeptide LQG did show reduced BUN concentration early in the experiment (at 24 hours post-reperfusion) and mice administered VLPALPQ (SEQ ID NO:5) did much better in terms of reduced BUN concentration late in the experiment (at 72 hours post-reperfusion) than the control group (PBS) or the group administered the other oligopeptides, with more mice surviving and the serum urea levels being much lower than in the other groups.

---

## TABLE 2

<table>
<thead>
<tr>
<th>Peptide</th>
<th>1 = 0 hr</th>
<th>2 hr</th>
<th>24 hr</th>
<th>72 hr</th>
<th>C-term: CARBOXYL</th>
<th>N-term: FREE</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>Mean</td>
<td>8.16667</td>
<td>4.03333</td>
<td>38.86364</td>
<td>32.8875</td>
<td>LAGV (SEQ ID NO:4)</td>
</tr>
<tr>
<td></td>
<td>sd</td>
<td>1.774658</td>
<td>1.015599</td>
<td>14.54711</td>
<td>14.31282</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>18</td>
<td>3</td>
<td>11</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>B</td>
<td>Mean</td>
<td>9.713333</td>
<td>16.62</td>
<td>26.36</td>
<td>22.31</td>
<td>AQGV (SEQ ID NO:2)</td>
</tr>
<tr>
<td></td>
<td>sd</td>
<td>1.882722</td>
<td>2.185203</td>
<td>20.62105</td>
<td>15.96444</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>30</td>
<td>10</td>
<td>20</td>
<td>10</td>
<td></td>
</tr>
<tr>
<td>C</td>
<td>Mean</td>
<td>10.15185</td>
<td>18.13333</td>
<td>59.24375</td>
<td>74.4</td>
<td>Lag</td>
</tr>
<tr>
<td></td>
<td>SD</td>
<td>1.789794</td>
<td>1.88326</td>
<td>16.19662</td>
<td>33.12546</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>29</td>
<td>6</td>
<td>6</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>D</td>
<td>Mean</td>
<td>8.303846</td>
<td>17.7</td>
<td>66.75625</td>
<td>91.18333</td>
<td>AQG</td>
</tr>
<tr>
<td></td>
<td>SD</td>
<td>1.502127</td>
<td>1.561135</td>
<td>24.50445</td>
<td>51.22154</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>26</td>
<td>8</td>
<td>16</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>E</td>
<td>Mean</td>
<td>8.403846</td>
<td>17.13</td>
<td>66.23333</td>
<td>104.0167</td>
<td>MTR</td>
</tr>
<tr>
<td></td>
<td>SD</td>
<td>1.730076</td>
<td>1.625526</td>
<td>17.55069</td>
<td>48.97193</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>26</td>
<td>10</td>
<td>6</td>
<td>6</td>
<td></td>
</tr>
<tr>
<td>F</td>
<td>Mean</td>
<td>7.462963</td>
<td>15.08571</td>
<td>34.57368</td>
<td>39.8375</td>
<td>MTRV (SEQ ID NO:1)</td>
</tr>
<tr>
<td></td>
<td>SD</td>
<td>1.338526</td>
<td>1.429041</td>
<td>15.18083</td>
<td>21.45973</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>30</td>
<td>7</td>
<td>18</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>G</td>
<td>Mean</td>
<td>8.256667</td>
<td>13.58</td>
<td>37.79375</td>
<td>37.6375</td>
<td>VPALPQ (SEQ ID NO:5)</td>
</tr>
<tr>
<td></td>
<td>SD</td>
<td>1.304021</td>
<td>1.927462</td>
<td>18.33007</td>
<td>29.32872</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>30</td>
<td>7</td>
<td>18</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>H</td>
<td>Mean</td>
<td>8.423333</td>
<td>16.24</td>
<td>62.4</td>
<td>47.05</td>
<td>VLPA (SEQ ID NO:6)</td>
</tr>
<tr>
<td></td>
<td>SD</td>
<td>1.255521</td>
<td>1.370482</td>
<td>13.33867</td>
<td>20.92728</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>30</td>
<td>10</td>
<td>9</td>
<td>7</td>
<td></td>
</tr>
<tr>
<td>I</td>
<td>Mean</td>
<td>7.518182</td>
<td>17.53333</td>
<td>56.08333</td>
<td>73.1778</td>
<td>LQGV (SEQ ID NO:3)</td>
</tr>
<tr>
<td></td>
<td>SD</td>
<td>1.537356</td>
<td>2.956913</td>
<td>14.53753</td>
<td>23.3083</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>22</td>
<td>3</td>
<td>18</td>
<td>9</td>
<td></td>
</tr>
<tr>
<td>J</td>
<td>Mean</td>
<td>7.82069</td>
<td>16.75</td>
<td>26.74</td>
<td>83.95714</td>
<td>LQG</td>
</tr>
<tr>
<td></td>
<td>SD</td>
<td>1.330515</td>
<td>1.44123</td>
<td>15.51796</td>
<td>40.32129</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>29</td>
<td>8</td>
<td>9</td>
<td>8</td>
<td></td>
</tr>
<tr>
<td>PBS</td>
<td>Mean</td>
<td>8.172414</td>
<td>15.0875</td>
<td>56.81</td>
<td>82.075</td>
<td></td>
</tr>
<tr>
<td></td>
<td>SD</td>
<td>1.540069</td>
<td>2.215167</td>
<td>22.4659</td>
<td>34.82713</td>
<td></td>
</tr>
<tr>
<td></td>
<td>N</td>
<td>29</td>
<td>8</td>
<td>15</td>
<td>4</td>
<td></td>
</tr>
</tbody>
</table>
At 24 hour post-reperfusion statistical analyses revealed P-values of:

A. \( p = 0.0491 \) NMPF-47 LAGV (SEQ ID NO: 4)
B. \( p = 0.0006 \) NMPF-46 AQGV (SEQ ID NO: 2)
C. \( p = 0.9246 \) NMPF-44 LAG
D. \( p = 0.4043 \) NMPF-43 AQG
E. \( p = 0.1948 \) NMPF-12 MTR
F. \( p = 0.0106 \) NMPF-11 MTR
G. \( p = 0.1389 \) NMPF-7 VLPALPQ (SEQ ID NO: 5)
H. \( p = 0.5613 \) NMPF-6 VLPALP (SEQ ID NO: 6)
I. \( p = 0.9301 \) NMPF-4 LQGV (SEQ ID NO: 3)
J. \( p = 0.0030 \) NMPF-3 LQG

P values were calculated by Mann Whitney U-test (SPSS for Windows).

Example 4

To determine dose-response relationships, two peptides (D (AQG), having a good effect on mortality on the mice tested in Example 1) and B (AQGV (SEQ ID NO:2), also having superior effect on BUN of the mice tested in Example 1) were also tested in a dose-response manner in the mice test as described above. Peptides were tested at 0.3, 1.3, 10 and 30 mg/kg dosages given as described in Example 1. The results can be seen in FIG. 2. P values (calculated by Mann Whitney U-test (SPSS for Windows)) of serum urea levels of PBS compared to peptide D groups at 72 hours post-clamping were at 0.3 mg/kg 0.001, at 1 mg/kg 0.009, at 3 mg/kg 0.02, at 10 mg/kg 0.000, and at 30 mg/kg 0.23, for peptide B groups these P-values were 0.88, 0.054, 0.000, 0.001 and 0.003. As can be seen, peptide D (AQG) did reduce BUN levels surprisingly well at the lower dosages tested, as compared with peptide B (AQGV (SEQ ID NO:2)), while the beneficial effect on mortality was also still notable at the lower dosages tested.

### TABLE 3

<table>
<thead>
<tr>
<th>Mortality in dose-response experiment</th>
<th>PBS</th>
<th>AQG 0.3 mg/kg</th>
<th>AQG 1.0 mg/kg</th>
<th>AQG 3.0 mg/kg</th>
<th>AQG 10.0 mg/kg</th>
<th>AQG 30.0 mg/kg</th>
<th>AQGV (SEQ ID NO: 2) 0.3 mg/kg</th>
<th>AQGV (SEQ ID NO: 2) 1.0 mg/kg</th>
<th>AQGV (SEQ ID NO: 2) 3.0 mg/kg</th>
<th>AQGV (SEQ ID NO: 2) 10.0 mg/kg</th>
<th>AQGV (SEQ ID NO: 2) 30.0 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 h</td>
<td>0-9</td>
<td>2-8</td>
<td>1-8</td>
<td>0-8</td>
<td>1-8</td>
<td>0-8</td>
<td>0-9</td>
<td>2-10</td>
<td>1-8</td>
<td>0-10</td>
<td>0-8</td>
</tr>
<tr>
<td>72 h</td>
<td>2-8</td>
<td>1-8</td>
<td>0-8</td>
<td>1-8</td>
<td>2-10</td>
<td>2-8</td>
<td>0-10</td>
<td>1-8</td>
<td>0-8</td>
<td>0-10</td>
<td>0-8</td>
</tr>
</tbody>
</table>

### TABLE 4

<table>
<thead>
<tr>
<th>Urea Levels in dose-response experiment</th>
<th>PBS</th>
<th>Peptide D (AQG) 0.3 mg/kg</th>
<th>Peptide D (AQG) 1.0 mg/kg</th>
<th>Peptide D (AQG) 3.0 mg/kg</th>
<th>Peptide D (AQG) 10.0 mg/kg</th>
<th>Peptide D (AQG) 30.0 mg/kg</th>
<th>Peptide B (AQGV (SEQ ID NO: 2)) 0.3 mg/kg</th>
<th>Peptide B (AQGV (SEQ ID NO: 2)) 1.0 mg/kg</th>
<th>Peptide B (AQGV (SEQ ID NO: 2)) 3.0 mg/kg</th>
<th>Peptide B (AQGV (SEQ ID NO: 2)) 10.0 mg/kg</th>
<th>Peptide B (AQGV (SEQ ID NO: 2)) 30.0 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>24 h</td>
<td>57.8</td>
<td>38.4</td>
<td>48.4</td>
<td>39.3</td>
<td>46.8</td>
<td>52.8</td>
<td>62.4</td>
<td>50.0</td>
<td>37.4</td>
<td>41.2</td>
<td>47.8</td>
</tr>
<tr>
<td>72 h</td>
<td>85.4</td>
<td>30.4</td>
<td>38.4</td>
<td>40.3</td>
<td>25.8</td>
<td>59.8</td>
<td>86.7</td>
<td>52.6</td>
<td>19.6</td>
<td>37.1</td>
<td>38.0</td>
</tr>
</tbody>
</table>

### TABLE 5

<table>
<thead>
<tr>
<th>statistical significance/p values (Mann Whitney U-Test) of serum urea levels in dose-response experiment 72 hours post-clamping</th>
<th>PBS</th>
<th>AQG 0.3 mg/kg</th>
<th>AQG 1.0 mg/kg</th>
<th>AQG 3.0 mg/kg</th>
<th>AQG 10.0 mg/kg</th>
<th>AQG 30.0 mg/kg</th>
<th>AQGV (SEQ ID NO: 2) 0.3 mg/kg</th>
<th>AQGV (SEQ ID NO: 2) 1.0 mg/kg</th>
<th>AQGV (SEQ ID NO: 2) 3.0 mg/kg</th>
<th>AQGV (SEQ ID NO: 2) 10.0 mg/kg</th>
<th>AQGV (SEQ ID NO: 2) 30.0 mg/kg</th>
</tr>
</thead>
<tbody>
<tr>
<td>72 h</td>
<td>NA</td>
<td>0.009</td>
<td>0.009</td>
<td>0.02</td>
<td>0.000</td>
<td>0.23</td>
<td>0.88</td>
<td>0.054</td>
<td>0.000</td>
<td>0.000</td>
<td>0.003</td>
</tr>
</tbody>
</table>
SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 6

<210> SEQ ID NO 1
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized Peptide

<400> SEQUENCE: 1
Met Thr Arg Val

<210> SEQ ID NO 2
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized Peptide

<400> SEQUENCE: 2
Ala Gln Gly Val

<210> SEQ ID NO 3
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized Peptide

<400> SEQUENCE: 3
Leu Gln Gly Val

<210> SEQ ID NO 4
<211> LENGTH: 4
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized Peptide

<400> SEQUENCE: 4
Leu Ala Gly Val

<210> SEQ ID NO 5
<211> LENGTH: 7
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized Peptide

<400> SEQUENCE: 5
Val Leu Pro Ala Leu Pro Gln

<210> SEQ ID NO 6
<211> LENGTH: 6
<212> TYPE: PRT
<213> ORGANISM: Artificial Sequence
<220> FEATURE:
<223> OTHER INFORMATION: Synthesized Peptide
What is claimed is:

1. An isolated oligopeptide consisting of the amino acid sequence of SEQ ID NO: 2 or a pharmaceutically acceptable salt thereof.

2. A pharmaceutical composition comprising a peptide consisting of the amino acid sequence of SEQ ID NO: 2 or a pharmaceutically acceptable salt thereof.

3. The pharmaceutical composition of claim 2 further comprising a pharmaceutically acceptable carrier, adjuvant, diluent, excipient or any mixtures thereof.

4. An isolated oligopeptide consisting of the amino acid sequence of SEQ ID NO: 2.

   ✫ ✫ ✫ ✫ ✫
On the title page:
In ITEM (73) Assignee: change “Biotemp” to --Biotemp--

In ITEM (56) References Cited:
OTHER PUBLICATIONS
Page 1, 2nd column,
1st line of the 2nd entry (line 45), change “Failure, American” to --Failure, American--

Page 2, 1st column,
3rd line of the 5th entry (line 72), change “Interferon gamma, ” “ to --Interferon-gamma,--

Page 3, 2nd column,
2nd line of the 3rd entry (line 9), change “VersUS -Host Disease by Human Chorionic gonadotropin,” “23(1)” to --versus Host-Disease by Human Chorionic Gonadotropin,” 23(1)--

Signed and Sealed this
Seventh Day of August, 2012

David J. Kappos
Director of the United States Patent and Trademark Office